(3-Chloroacetyl)-indole, a Novel Allosteric AKT Inhibitor, Suppresses Colon Cancer Growth In Vitro and In Vivo

被引:28
|
作者
Kim, Dong Joon [1 ]
Reddy, Kanamata [1 ]
Kim, Myoung Ok [1 ]
Li, Yan [1 ]
Nadas, Janos [1 ]
Cho, Yong-Yeon [1 ,2 ]
Kim, Jong-Eun [1 ]
Shim, Jung-Hyun [3 ]
Song, Nu Ry [4 ]
Carper, Andria [1 ]
Lubet, Ronald A. [5 ]
Bode, Ann M. [1 ]
Dong, Zigang [1 ]
机构
[1] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA
[2] Catholic Univ Korea, Dept Pharmacol, Coll Pharm, Puchon, South Korea
[3] Soonchunhyang Univ, Dept Biochem, Coll Med, Cheonan, South Korea
[4] Seoul Natl Univ, Dept Agr Biotechnol, Seoul, South Korea
[5] NCI, Bethesda, MD 20892 USA
关键词
CELL-CYCLE ARREST; PLECKSTRIN-HOMOLOGY-DOMAIN; KINASE-B; DIETARY INDOLE-3-CARBINOL; 3-KINASE/AKT PATHWAY; TARGET; RESISTANCE; UBIQUITINATION; IDENTIFICATION; CHEMOTHERAPY;
D O I
10.1158/1940-6207.CAPR-11-0158
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Indole-3-carbinol (I3C) is produced in Brassica vegetables such as broccoli and cabbage and has been shown to inhibit proliferation and induce apoptosis in various cancer cells, including breast, prostate, colon, and leukemia. However, only high doses of I3C were shown to inhibit cell proliferation (IC50 = 200-300 mu mol/L). Our goal here was to develop a more potent antitumor agent by modifying the structure of I3C. We created I3C derivatives and found that (3-chloroacetyl)-indole (3CAI) more strongly inhibited colon cancer cell growth than I3C. In addition, by screening 85 kinases in a competitive kinase assay, we found that 3CAI was a specific AKT inhibitor. AKT is a serine/threonine kinase that plays a pivotal role in promoting transformation and chemoresistance by inducing proliferation and inhibiting apoptosis. Therefore, AKT is regarded as a critical target for cancer therapy. 3ICA, a derivative of I3C, is a potent and specific AKT inhibitor. This compound showed significant inhibition of AKT in an in vitro kinase assay and suppressed expression of AKT direct downstream targets such as mTOR and GSK3 beta as well as induced growth inhibition and apoptosis in colon cancer cells. In addition, oral administration of this potent AKT inhibitor suppressed cancer cell growth in an in vivo xenograft mouse model. Cancer Prev Res; 4(11); 1842-51. (C) 2011 AACR.
引用
收藏
页码:1842 / 1851
页数:10
相关论文
共 50 条
  • [41] Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
    Hrzenjak, Andelko
    Moinfar, Farid
    Kremser, Marie-Luise
    Strohmeier, Bettina
    Petru, Edgar
    Zatloukal, Kurt
    Denk, Helmut
    MOLECULAR CANCER, 2010, 9
  • [42] Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
    Hrzenjak, A.
    Moinfar, F.
    Kremser, M. L.
    Strohmeier, B.
    Petru, E.
    Zatloukal, K.
    Denk, H.
    EJC SUPPLEMENTS, 2010, 8 (05): : 65 - 65
  • [43] In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine
    Li, Zhijie
    Tan, Fei
    Liewehr, David J.
    Steinberg, Seth M.
    Thiele, Carol J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (11): : 758 - 770
  • [44] Isorhamnetin suppresses colon cancer cell growth through the PI3K-Akt-mTOR pathway
    Li, Chuan
    Yang, Xi
    Chen, Cheng
    Cai, Shaoxin
    Hu, Junbo
    MOLECULAR MEDICINE REPORTS, 2014, 9 (03) : 935 - 940
  • [45] The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
    Michael T Buckley
    Joanne Yoon
    Herman Yee
    Luis Chiriboga
    Leonard Liebes
    Gulshan Ara
    Xiaozhong Qian
    Dean F Bajorin
    Tung-Tien Sun
    Xue-Ru Wu
    Iman Osman
    Journal of Translational Medicine, 5
  • [46] The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
    Buckley, Michael T.
    Yoon, Joanne
    Yee, Herman
    Chiriboga, Luis
    Liebes, Leonard
    Ara, Gulshan
    Qian, Xiaozhong
    Bajorin, Dean F.
    Sun, Tung-Tien
    Wu, Xue-Ru
    Osman, Iman
    JOURNAL OF TRANSLATIONAL MEDICINE, 2007, 5 (1)
  • [47] A Small Molecule Inhibitor of the β-Catenin-TCF4 Interaction Suppresses Colorectal Cancer Growth In Vitro and In Vivo
    Shin, Seung Ho
    Lim, Do Young
    Reddy, Kanamata
    Malakhova, Margarita
    Liu, Fangfang
    Wang, Ting
    Song, Mengqiu
    Chen, Hanyong
    Bae, Ki Beom
    Ryu, Joohyun
    Liu, Kangdong
    Lee, Mee-Hyun
    Bode, Ann M.
    Dong, Zigang
    EBIOMEDICINE, 2017, 25 : 22 - 31
  • [48] An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo
    Cherrin, Craig
    Haskell, Kathleen
    Howell, Bonnie
    Jones, Raymond
    Leander, Karen
    Robinson, Ronald
    Watkins, Aubrey
    Bilodeau, Mark
    Hoffman, Jacob
    Sanderson, Philip
    Hartman, George
    Mahan, Elizabeth
    Prueksantanont, Thomayant
    Jiang, Guoqiang
    She, Qing-Bai
    Rosen, Neal
    Sepp-Lorenzino, Laura
    Defeo-Jones, Deborah
    Huber, Hans E.
    CANCER BIOLOGY & THERAPY, 2010, 9 (07) : 493 - 503
  • [49] Gastrin suppresses growth of CCK2 receptor expressing colon cancer cells by inducing apoptosis in vitro and in vivo
    Müerköster, S
    Isberner, A
    Arlt, A
    Witt, M
    Reimann, B
    Blaszczuk, E
    Werbing, V
    Fölsch, UR
    Schmitz, F
    Schäfer, H
    GASTROENTEROLOGY, 2005, 129 (03) : 952 - 968
  • [50] GS-19, a novel GSK inhibitor suppresses the growth of pancreatic cancer cells by inhibiting EGFR/AKT/STAT-3 signaling
    Ranjan, Alok
    Birkenfeld, Ashlee
    Lu, Jianyu
    Hua, Duy
    Srivastava, Sanjay K.
    CANCER RESEARCH, 2014, 74 (19)